These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 33938615)

  • 1. Opinions of adults affected with later-onset lysosomal storage diseases regarding newborn screening: A qualitative study.
    Lisi EC; Ali N
    J Genet Couns; 2021 Dec; 30(6):1544-1558. PubMed ID: 33938615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients' perspectives on newborn screening for later-onset lysosomal storage diseases.
    Lisi EC; Gillespie S; Laney D; Ali N
    Mol Genet Metab; 2016 Sep; 119(1-2):109-14. PubMed ID: 27591925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newborn Screening for Lysosomal Storage Disorders: Views of Genetic Healthcare Providers.
    Lisi EC; McCandless SE
    J Genet Couns; 2016 Apr; 25(2):373-84. PubMed ID: 26315880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health care practitioners' experience-based opinions on providing care after a positive newborn screen for Pompe disease.
    Davids L; Sun Y; Moore RH; Lisi E; Wittenauer A; Wilcox WR; Ali N
    Mol Genet Metab; 2021; 134(1-2):20-28. PubMed ID: 34602357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newborn screening for Pompe disease: Parental experiences and follow-up care for a late-onset diagnosis.
    Prakash S; Penn JD; Jackson KE; Dean LW
    J Genet Couns; 2022 Dec; 31(6):1404-1420. PubMed ID: 35915971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newborn screening for Pompe disease: impact on families.
    Pruniski B; Lisi E; Ali N
    J Inherit Metab Dis; 2018 Nov; 41(6):1189-1203. PubMed ID: 29594646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The patient journey of patients with Fabry disease, Gaucher disease and Mucopolysaccharidosis type II: A German-wide telephone survey.
    Mengel E; Gaedeke J; Gothe H; Krupka S; Lachmann A; Reinke J; Ohlmeier C
    PLoS One; 2020; 15(12):e0244279. PubMed ID: 33382737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newborn Screening for Lysosomal Storage Disorders.
    Anderson S
    J Pediatr Health Care; 2018; 32(3):285-294. PubMed ID: 29678259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newborn screening for lysosomal storage disorders.
    Nakamura K; Hattori K; Endo F
    Am J Med Genet C Semin Med Genet; 2011 Feb; 157C(1):63-71. PubMed ID: 21312327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newborn screening for lysosomal diseases: current status and potential interface with population medical genetics in Latin America.
    Giugliani R
    J Inherit Metab Dis; 2012 Sep; 35(5):871-7. PubMed ID: 22231381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.
    Rairikar MV; Case LE; Bailey LA; Kazi ZB; Desai AK; Berrier KL; Coats J; Gandy R; Quinones R; Kishnani PS
    Mol Genet Metab; 2017 Nov; 122(3):99-107. PubMed ID: 28951071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri.
    Hopkins PV; Campbell C; Klug T; Rogers S; Raburn-Miller J; Kiesling J
    J Pediatr; 2015 Jan; 166(1):172-7. PubMed ID: 25444528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanding newborn screening for lysosomal disorders: opportunities and challenges.
    Waggoner DJ; Tan CA
    Dev Disabil Res Rev; 2011; 17(1):9-14. PubMed ID: 22447749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newborn Screening for 6 Lysosomal Storage Disorders in China.
    Chang S; Zhan X; Liu Y; Song H; Gong Z; Han L; Maegawa GHB; Gu X; Zhang H
    JAMA Netw Open; 2024 May; 7(5):e2410754. PubMed ID: 38739391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary involvement in selected lysosomal storage diseases and the impact of enzyme replacement therapy: A state-of-the art review.
    Jezela-Stanek A; Chorostowska-Wynimko J; Tylki-Szymańska A
    Clin Respir J; 2020 May; 14(5):422-429. PubMed ID: 31912638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The New York pilot newborn screening program for lysosomal storage diseases: Report of the First 65,000 Infants.
    Wasserstein MP; Caggana M; Bailey SM; Desnick RJ; Edelmann L; Estrella L; Holzman I; Kelly NR; Kornreich R; Kupchik SG; Martin M; Nafday SM; Wasserman R; Yang A; Yu C; Orsini JJ
    Genet Med; 2019 Mar; 21(3):631-640. PubMed ID: 30093709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatable lysosomal storage diseases in the advent of disease-specific therapy.
    Peters H; Ellaway C; Nicholls K; Reardon K; Szer J
    Intern Med J; 2020 Nov; 50 Suppl 4():5-27. PubMed ID: 33210402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detecting multiple lysosomal storage diseases by tandem mass spectrometry--a national newborn screening program in Taiwan.
    Liao HC; Chiang CC; Niu DM; Wang CH; Kao SM; Tsai FJ; Huang YH; Liu HC; Huang CK; Gao HJ; Yang CF; Chan MJ; Lin WD; Chen YJ
    Clin Chim Acta; 2014 Apr; 431():80-6. PubMed ID: 24513544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newborn screening for six lysosomal storage disorders in a cohort of Mexican patients: Three-year findings from a screening program in a closed Mexican health system.
    Navarrete-Martínez JI; Limón-Rojas AE; Gaytán-García MJ; Reyna-Figueroa J; Wakida-Kusunoki G; Delgado-Calvillo MDR; Cantú-Reyna C; Cruz-Camino H; Cervantes-Barragán DE
    Mol Genet Metab; 2017 May; 121(1):16-21. PubMed ID: 28302345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of newborn screening for lysosomal disorders.
    Wasserstein MP; Orsini JJ; Goldenberg A; Caggana M; Levy PA; Breilyn M; Gelb MH
    Neurosci Lett; 2021 Aug; 760():136080. PubMed ID: 34166724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.